• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

    7/17/23 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTCT alert in real time by email

    SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development.

    "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "Pierre's extensive global experience in finance and healthcare advisory will be incredibly helpful as we continue to build the PTC of tomorrow. Having known Pierre over the past several years, I am confident his knowledge, experience and passion to help patients make him a great addition to the PTC family."

    Prior to joining Perella Weinberg, Pierre worked as a healthcare investment banker at Barclays Capital in London. Previously, he was a venture capital analyst at Société Générale Asset Management in Paris, where he focused on early-stage investments in the biotechnology sector. Mr. Gravier began his career as a scientist at Ferring Pharmaceuticals. Pierre holds a master's degree in finance from ESCP Business School and a Master of Science in bioengineering from the University of Technology of Compiègne.

    "I am excited to join the patient-focused and mission-driven PTC team and look forward to supporting our continued efforts to deliver transformational therapies to patients with high unmet medical need," said Pierre Gravier.

    About PTC Therapeutics, Inc.

    PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn and Twitter at @PTCBio.

    For More Information:

    Investors:

    Kylie O'Keefe

    +1 (908) 300-0691

    [email protected]

    Media:

    Jeanine Clemente

    +1 (908) 912-9406

    [email protected]

    Forward-Looking Statements:

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance," "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

    PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

    The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

    Cision View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-appoints-experienced-healthcare-finance-strategist-pierre-gravier-as-chief-financial-officer-301878977.html

    SOURCE PTC Therapeutics, Inc.

    Get the next $PTCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTCT

    DatePrice TargetRatingAnalyst
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    5/7/2025$40.00Sell → Neutral
    Citigroup
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    3/7/2025$55.00Sector Perform
    Scotiabank
    12/13/2024$45.00 → $67.00Equal-Weight → Overweight
    Morgan Stanley
    12/3/2024$39.00 → $63.00Sector Perform → Outperform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    9/4/2024$44.00Outperform
    Robert W. Baird
    More analyst ratings

    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      – Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.  "Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year r

      5/6/25 4:01:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC518 PIVOT-HD Study Achieves Primary Endpoint

      - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disea

      5/5/25 7:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WARREN, N.J., May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on April 

      5/1/25 4:30:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PTC Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00

      5/9/25 8:40:13 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded PTC Therapeutics from Sell to Neutral and set a new price target of $40.00

      5/7/25 8:34:42 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded PTC Therapeutics from Underperform to Neutral and set a new price target of $55.00 from $41.00 previously

      3/11/25 7:43:05 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

      SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein

      7/17/23 4:30:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      12/14/23 4:38:32 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $PTCT
    Financials

    Live finance-specific insights

    See more
    • PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      – Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.  "Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year r

      5/6/25 4:01:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC518 PIVOT-HD Study Achieves Primary Endpoint

      - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disea

      5/5/25 7:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

      WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investors

      4/17/25 8:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      11/14/24 5:22:11 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      11/8/24 10:52:39 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      10/18/24 10:57:11 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $136,656 worth of shares (2,804 units at $48.74), decreasing direct ownership by 1% to 273,234 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      4/24/25 5:20:05 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold $42,114 worth of shares (897 units at $46.95), decreasing direct ownership by 1% to 75,997 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      4/4/25 5:20:04 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF BUSINESS OFFICER Pauwels Eric sold $630,104 worth of shares (11,220 units at $56.16), decreasing direct ownership by 13% to 72,640 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      3/18/25 5:20:05 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by PTC Therapeutics Inc.

      10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/6/25 4:34:25 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/6/25 4:03:36 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/5/25 7:55:12 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care